Compass Plots Path to FDA With ‘Meaningful’ Phase III Data for Psilocybin Drug in Depression

Although the company withheld detailed findings from the study of treatment-resistant depression, analysts at Stifel called COMP360’s efficacy “more than good enough” for registrational purposes.